Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omega-Formula is a nutraceutical dietary supplement developed by Guna S.p.a. for the management of borderline dyslipidemia and the maintenance of healthy cholesterol levels. The formulation's primary active ingredient is Monacolin K, a naturally occurring compound in red yeast rice (Monascus purpureus) that is chemically identical to lovastatin and functions as a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Additionally, the supplement contains micronized seeds of the Baobab tree (Adansonia digitata), which provide dietary fiber and antioxidant polyphenols, and a synergistic blend of B vitamins (B6, B12, and folic acid) that facilitate the metabolism of homocysteine. By addressing both cholesterol production and homocysteine levels, Omega-Formula aims to provide comprehensive cardiovascular support. It is administered orally in tablet form and is commercially available as a food supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omega-Formula.